
2018 MHRA GMP Inspection Deficiencies
Provided is an overview of MHRA’s 2018 GMP inspection deficiencies parsed by Annex and Chapter, and Critical and Major deficiencies.
Provided is an overview of MHRA’s 2018 GMP inspection deficiencies parsed by Annex and Chapter, and Critical and Major deficiencies.
FDA posted one warning letter to a pharmaceutical firm and 15 to firms that sell CBD products.
We took a snapshot of the seven warning letters FDA sent to food and dietary supplement companies that were posted in October. Violations range from misbranding to the presence of Listeria monocytogenes.
We cover the three FDA warning letters published this week including the second one to Torrent Pharmaceuticals in October 2019.
Join FDAzilla’s GMP Quality Expert Jerry Chapman for an informative 1-hour webinar on assessing legacy products for potential GMP compliance gaps and pitfalls.
A busy week for enforcement. Included in this week of warning letters are Dollar Tree (in which FD&C Act is cited rather than CFR), Cadila Healthcare Limited, and Mylan Laboratories Limited among others.
We put together a review of notable 483s from the month of October, including 483s posted by FDA throughout the month and most-purchased 483s from the FDAzilla Store.
Yet another week with a preponderance of warning letters issued by the Center for Tobacco Products. We cover one warning letter issued to an OTC manufacturer in China.
A slow week for drug and device warning letters as FDA continues their enforcement focus on e-cigarette suppliers. Enforcement this week includes a lone GMP warning letter to a PET drug manufacturer.
SEARCH LESS KNOW MORE
The essential tool for compliance, regulatory, and quality professionals